FDA grants Eiger's breakthrough drug for hepatitis D infection

, eiger(http://announced that the u.SFood andDrug(http://Administration (
FDA(http://) has granted lonafarnib a breakthrough drug (BTD) for the treatment of hepatitis D virus (HDV) infectionlonafarnib is a pioneering isoprene inhibitor developed for the treatment of HDV infectionThe FDA granted lo
nafarnib BTD, based on data from multiple Phase II clinical studiesThese studies assessed the efficacy and safety of lonafarnib-based treatment of HDV infections, and the data showed that lonafarnib-based protocols reached a joint primary endpoint of reducing HDV RNA levels by 2log10 and normalizing the level of alaninaminosoase (ALT), reflecting improved liver conditions and virological responseslonafarnib
lonafarnib is a distinct late-stage oral activity inhibitor with fanici transfer enzyme as a target, and farniki transfer enzyme is involved in protein modification through a process called isopreneHDV uses this host cell process in liver cells to complete a critical step in its life cycle lonafarnib inhibits the isopreneization of HDV replication in liver cells, blocking the virus life cycle during the virus assembly phase Lonafarnib has been treated in more than 120 cases of HDV infection at the International Academic Center, and the drug is currently in the midst of a critical phase III clinical study in the United States and the European Union, lonafarnib has been granted orphan drug status and fast-track status in the United States Lonafarnib has not been approved for any indications, and the drug was obtained from the Mercadon authorization